Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp147 | Neuroendocrinology | ECE2018

Macrophages involvement in neuroendocrine tumor behaviour and progression

Boemi Ilena , Vitali Eleonora , Veronesi Giulia , Zerbi Alessandro , Lania Andrea

Neuroendocrine tumors (NETs) are rare neoplasms showing a wide spectrum of clinical behaviors. The therapeutic options available for NET treatment are rarely curative and most are palliative, as NETs frequently show resistance to pharmacological therapy. Cancers develop in complex tissue environments, which they depend upon for sustained growth, invasion and metastasis. A major characteristic of the tumor microenvironment is inflammatory cell infiltration, where tumor-associat...

ea0049oc7.4 | Cardiovascular endocrinology (1) | ECE2017

A novel insight into the anticancer mechanism of metformin in Pancreatic Neuroendocrine Tumor cells

Vitali Eleonora , Piccinini Sara , Boemi Ilena , Tresoldi Alberto , Zerbi Alessandro , Carnaghi Carlo , Spada Anna , Lania Andrea

Metformin (1.1-dimethylbiguanide hydrochloride), a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers, including neuroendocrine tumors. Recently, a potential synergistic activity between metformin and octreotide (SSA) in Pancreatic Neuroendocrine Tumors (P-NETs) has been proposed. AIP (aryl hydrocarbon receptor-interacting protein) acts as tumor suppressor gene in neuroendocrine tumors at pituitary level and it ...

ea0037ep1121 | Endocrine tumours | ECE2015

Identification of human SST2 somatostatin receptor domains involved in receptor internalization and signaling in pancreatic neuroendocrine tumors

Cambiaghi Valeria , Vitali Eleonora , Mantovani Giovanna , Spada Anna , Peverelli Erika , Lania Andrea

Somatostatin exerts its inhibitory effects on hormone secretion and cell proliferation via five receptors subtypes (SST1-SST5). After agonist binding, receptor residues mainly located in the carboxyl terminal (CT) and in the third intracellular loop (IC3) are phosphorylated and β-arrestins are recruited to drive SSTRs internalization.Aim of the study is to characterize the intracellular mechanisms responsible for SST2 internalization and identify th...

ea0070aep563 | Pituitary and Neuroendocrinology | ECE2020

Macrophages involvement in neuroendocrine tumor behaviour and progression

Boemi Ilena , Vitali Eleonora , Trivellin Giampaolo , Smiroldo Valeria , Lavezzi Elisabetta , Zerbi Alessandro , Stratakis Constantine , Lania Andrea

Neuroendocrine neoplasms (NENs) are rare tumour showing a wide spectrum of clinical behaviours. Therapeutic options available for NET treatment are rarely curative and mostly palliative, as NETs frequently show resistance to pharmacological therapy. Cancers develop in complex tissue environments, which they depend on. Tumour-associated macrophages (TAMs) are a major cellular component of the tumour microenvironment. Two polarized state of macrophages are described in literatur...

ea0032p827 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

cAMP exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A and exchange proteins directly activated by cAMP

Vitali Eleonora , Peverelli Erika , Mantovani Giovanna , Giardino Elena , Lania Andrea G. , Beck-Peccoz Paolo , Spada Anna

cAMP is implicated in the inhibition or stimulation of proliferation depending on cell type. The activation of cAMP–PKA pathway generates proliferative signals in GH-secreting adenomas whereas this effect is not present, or even opposite, in non-functioning pituitary cells (NFPA). Although cAMP effects were initially attributed to PKA activation, recently the discovery of two cAMP-activated guanine nucleotide exchange factors (Epac1,2) was proposed as a novel mechanism fo...

ea0022p720 | Signal transduction | ECE2010

Role of filamin-A in the regulation of dopamine D2 receptor localization and signaling in a lactotroph cell model

Mantovani Giovanna , Peverelli Erika , Ferrero Stefano , Vitali Eleonora , Beck-Peccoz Paolo , Spada Anna , Lania Andrea

Dopamine agonists (DA) inhibit prolactin (PRL) secretion and expression on the pituitary lactotrophs by binding dopamine D2 receptor. Prolactinomas are the most common secreting pituitary adenomas, and DA are the first choice for their treatment because they reduce PRL levels and tumor size. However, a subset of patients is resistant to DA. The mechanisms involved in DA resistance are not fully understood, although decreased expression of D2 receptor or altered signal transduc...

ea0081ep594 | Endocrine-Related Cancer | ECE2022

New CDKN1b mutation in multiple endocrine neoplasia type 4 and brief literature review on clinical management.

Brunetti Alessandro , Lavezzi Elisabetta , Bertuzzi Alexia , Nappo Gennaro , Laffi Alice , Pedicini Vittorio , Vitali Eleonora , Trivellin Giampaolo , Mazziotti Gherardo , Lania Andrea

Background: The fourth type of Multiple Endocrine Neoplasia (MEN) is a rare variant of MEN presenting a MEN1-like phenotype and originating from a germline mutation in CDKN1B. However, due to the small number of cases documented in literature, the peculiar clinical features of MEN4 are still largely unknown, and clear indications about the clinical management of these patients are currently lacking. In order to enlarge our knowledge on MEN4 and to better typify the clinical fe...

ea0041gp111 | Endocrine Tumours | ECE2016

Implication of Filamin A in pulmonary neuroendocrine tumors aggressiveness and progression

Vitali Eleonora , Ferrero Stefano , Peverelli Erika , Veronesi Giulia , Alloisio Marco , Santambrogio Luigi , Spada Anna , Mantovani Giovanna , Lania Andrea

Pulmonary neuroendocrine tumors (PNTs) comprise a spectrum of neoplasms, ranging from low grade carcinoids to the highly malignant small cell lung cancers. Several studies identified cytoskeleton protein Filamin A (FLNA) as determinant in cancer progression and metastasis. To date, the role of FLNA in PNTs aggressiveness and progression is still unknown.To address this question, we decided: i) to evaluate FLNA expression in PNTs ranging from typical carc...

ea0037gp.28.05 | Endocrine tumours and neoplasia – NETS | ECE2015

Filamin-A is involved in stabilisation, signal transduction, and angiogenesis regulation mediated by somatostatin receptor 2 in pancreatic neuroendocrine tumors

Vitali Eleonora , Cambiaghi Valeria , Loiarro Federica , Zerbi Alessandro , Colombo Piergiuseppe , Spada Anna , Mantovani Giovanna , Peverelli Erika , Carnaghi Carlo , Lania Andrea

Somatostatin receptor type 2 (SST2) is the main pharmacological target of long-acting somatostatin analogues (SSA) widely used in patients with pancreatic neuroendocrine tumours (P-NETs). A subset of patients is resistant to SSA, although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein interactions as determinant in receptor anchoring, expression and signalling. Since SST2 was recently demonstrated to a...

ea0035p517 | Endocrine tumours and neoplasia | ECE2014

The effects of cAMP in different neuroendocrine tumorous cells: the role of Epac and PKA in cell proliferation and cell adhesion

Vitali Eleonora , Cambiaghi Valeria , Zerbi Alessandro , Peverelli Erika , Mantovani Giovanna , Loiarro Federica , Carnaghi Carlo , Spada Anna , Lania Andrea

cAMP is an ubiquitous second messenger that is implicated in the regulation of a wide variety of cell functions, including cell proliferation that is differently affected depending on the cell type. Although the effects exerted by cAMP were initially attributed to PKA activation, two exchange proteins directly activated by cAMP (Epac1/2) have been identified as cAMP targets able to mediate several cAMP effects. Aim of this study was to investigate the effect of cAMP on neuroen...